

PRIMARY CARE REPORTS

The Practical CME Journal for Primary Care and Family Physicians

November 2017

VOL. 23, NO. 11

AUTHORS

Raquel M. Schears, MD, MPH, MBA, FACEP, Brandeis University, The Heller School for Social Policy and Management, Executive MBA for Physicians Program, Waltham, MA

Catherine A. Marco, MD, FACEP, Professor, Department of Emergency Medicine, Wright State University Boonshoft School of Medicine, Dayton, OH

PEER REVIEWER

Steven M. Winograd, MD, FACEP, Queens Hospital Center, Jamaica, NY; Core Faculty, Attending Emergency Physician.

STATEMENT OF FINANCIAL DISCLOSURE

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Wise (editor) reports he is involved with sales for CNS Vital Signs. Dr. Schears (author), Dr. Marco (author), Dr. Winograd (peer reviewer), Ms. Coplin (executive editor), Ms. Mark (executive editor), and Ms. Hatcher (AHC Media editorial group manager) report no financial relationships with companies related to the field of study covered by this CME activity.

AHC Media

A RELIAS LEARNING COMPANY

Management of Skin and Soft Tissue Infections

Skin and soft tissue infections (SSTIs) are encountered commonly in primary care practices, presenting as a range of disorders, from uncomplicated cellulitis, impetigo, folliculitis, erysipelas, and focal abscesses to necrotizing fasciitis. Each year between 1998–2006 in the United States, there were 650,000 hospital admissions for cellulitis, with estimates of 14.5 million cases annually treated as outpatients, accounting for \$3.7 billion in ambulatory care costs.^{1,2}

Patients with simple cellulitis typically present with an area of expanding erythema that is warm and tender to touch. (*See Figure 1.*) Other features may include swelling and fluid drainage. The diagnosis of cellulitis is made primarily by history and physical findings, and differentiated from other skin and soft tissue findings by appearance. (*See Table 1.*) Diagnostic modalities may be indicated to reliably discern cellulitis from other more serious infections or a true emergency, such as necrotizing cellulitis. Once the diagnosis of cellulitis is made, empiric treatment should be instituted based on common pathogens. The usual pathogenic organisms include

Figure 1. Cellulitis



Image courtesy of J. Stephan Stapczynski, MD.

EXECUTIVE SUMMARY

Soft tissue infections, ranging from uncomplicated cellulitis, impetigo, folliculitis, erysipelas, and focal abscesses to necrotizing fasciitis, commonly are encountered in ambulatory practices.

- About 650,000 patients are hospitalized each year, with 14.5 million cases annually treated as outpatients, accounting for \$3.7 billion in ambulatory care costs.
- Blood cultures and skin cultures have a low rate of positivity and low impact on treatment decisions. Tissue cultures have low yield and little effect on clinical decision-making.

- Empiric treatment of primary cellulitis typically is initiated with antibiotics effective against the two most common pathogens: beta-hemolytic streptococci and methicillin-sensitive *Staphylococcus aureus*.
- Infectious Diseases Society of America guidelines guide empiric therapy. Purulent cellulitis should be treated with 5-10 days of antibiotics, such as clindamycin, trimethoprim-sulfamethoxazole, doxycycline, minocycline, or linezolid, to cover methicillin-resistant *Staphylococcus aureus*. Oral therapy is just as effective as intravenous treatment for uncomplicated cellulitis.

beta-hemolytic streptococci and methicillin-sensitive *Staphylococcus aureus* (MSSA).¹ Failure to respond to appropriate first-line antibiotics within five days of initiating therapy may indicate resistant organisms, polymicrobial infection, pseudocellulitic mimicry, underlying immunosuppression, or a deep space infection not treatable with oral antibiotics.

Although generally of little concern for patients with cellulitis and other superficial skin infections, the initial evaluation of patients presenting for care and treatment of skin infections consists of assessment and stabilization of life and limb threats that begins with assessment and management of airway, breathing, and circulation. In all patients with skin and soft tissue infections, assessment of circulation in the involved region is important. The capillary refill should be checked in the involved area and, if the infection is on a limb, the arterial pulses above and below the area should be checked. If pulses cannot be palpated, Doppler assessment of flow is advised. Absent palpable pulses and Doppler flow indicate potential limb-threatening ischemia. A vascular surgeon should be consulted and additional imaging studies, such as computed tomography (CT) angiography, typically are done.

After assessing arterial inflow, look for signs suggestive of impaired venous outflow, such as dependent edema, stasis dermatitis, and prominent varicose veins on the legs. Venous

insufficiency may mimic cellulitis and impair the response to antibiotic therapy.

Physicians should consider diseases and injuries that are the most serious and treatable. Because cellulitis can be challenging to diagnose properly, hospital admission and further clinical deliberation may be prudent in cases of uncertain diagnosis.³ Because cellulitis generally is more responsive to treatment than other similar conditions (drug reactions, venous stasis, which may give a clue in their bilaterality), physicians often err on the side of initiating empiric treatment even when the diagnosis is uncertain.⁴ They also may admit patients with cellulitis to the hospital to monitor for worsening of the condition. However, the practice of hospitalizing patients provisionally diagnosed with cellulitis to validate the diagnosis and observe the response to empiric treatment has been questioned recently.^{5,6}

Empiric treatment of primary cellulitis starts with antibiotics effective against the two most common pathogens: beta-hemolytic streptococci and MSSA. Patients who have recurrent cellulitis or do not respond to initial therapy should be treated with antibiotics that have an expanded spectrum to include methicillin-resistant *Staphylococcus aureus* (MRSA). Consider expanded antibiotic spectrum to include MRSA in patients at risk for this pathogen, such as athletes, children, military recruits, intravenous drug abusers, prisoners, men who

have sex with men, nursing home residents, and those with prior MRSA exposure.^{1,8,14}

Epidemiology and Risk Factors

Impetigo occurs in about 20/1,000 people per year, and erysipelas occurs in about 1/1,000 people per year.⁹ Despite this high frequency, there are limited data on the frequency with which specific bacteria are associated with these infections.

Impetigo is a skin infection that is ubiquitous worldwide. It occurs most frequently among economically disadvantaged children in tropical or subtropical regions, but also is common in northern climates during summer months, and all epidemics show this seasonal proclivity.⁹ The incidence of impetigo is highest in children younger than 5 years of age, followed by children 5 to 14 years of age; the incidence then decreases rapidly in those between 14 and 44 years of age, and is at a minimum among the elderly (> 65 years of age).

Erysipelas affects mostly adults in their 60s and 70s and involves the lower extremities in more than 80% of cases.¹⁰ The incidence of lower-extremity cellulitis in Olmsted County, MN, was estimated at 2/1,000 people per year when both erysipelas and cellulitis affecting the leg were considered.¹¹ Predisposing factors are well identified for erysipelas or cellulitis of the leg, including disruption of the cutaneous barrier

Table 1. Clinical Findings of Skin Infections

Skin Infection	Clinical Findings
Cellulitis	Localized erythema, induration, warmth
Impetigo	Erythema, yellow or brown crusting; possible bullae
Erysipelas	Well-demarcated erythema with raised border, often facial; may have fever and systemic illness
Ecthyma	Erythema with dermal and epidermal erosions
Folliculitis	Papules, pustules associated with hair follicles
Furuncle	Erythema, fluctuance, pustules associated with hair follicles
Abscess	Erythema, warmth, fluctuance

(leg ulcer, wound, toe-web intertrigo, pressure ulcer), lymphedema, chronic edema, or local surgical operations. Toe-web intertrigo appears to be the main portal of entry with or without dermatophytes being coincident. Lymphedema is a very strong risk factor, but any type of edema is both a risk factor and a consequence of the disease.^{12,13} Other comorbidities, such as obesity or diabetes, and prior history of cellulitis are surprisingly less compelling as risk factors.

To date there are no consistent data on the prevalence or incidence of folliculitis and furunculosis in the community. However, there are reports of some individuals with repeated attacks of furunculosis. For most of these patients, the only identifiable predisposing factor is the carriage of *S. aureus* in the anterior nares. Twenty to forty percent of the general population harbors staphylococcal colonies in the nares.

There is literature on longitudinal outbreaks of furunculosis caused by MSSA as well as by MRSA.^{21,14} Risk factors for outbreaks include being part of a small community (i.e., family groups) and other settings involving close personal contact (i.e., athletics), inadequate hygiene, and exposure to others having furuncles.

Researchers in Chicago looked at community-acquired (CA)-MRSA

infections, which mainly manifested clinically as abscesses. These investigators identified risk factors including incarceration, African-American race/ethnicity, and residing in the close quarters of geocentric public housing complexes, and found an inverse correlation among the elderly residents of these urban settings.¹⁵

As noted above, outbreaks of epidemic furuncles due to CA-MRSA occur in young otherwise healthy people. In many U.S. cities, MRSA has become the most common pathogen isolated in the ED from patients with SSTIs.^{16,20} Bacterial endocarditis in patients with CA-MRSA furunculosis has emerged as a complication, but unfortunately there are no large, community-based prospective studies to assess the risk of endocarditis from MRSA SSTIs.

Clinical Findings of Cellulitis

Of the common bacterial skin infections, impetigo is the most common in children worldwide. It consists of superficial, nonfollicular, discrete, purulent lesions that are caused by *S. aureus* or beta-hemolytic streptococci and may have a honey-crusted, pustular, or cornflake-like appearance.

Boils (furuncles) are infections of the hair follicle and often are caused by *S. aureus*. Therefore, they may have

suppuration that extends to the deep dermis, where small abscess pockets can develop. Furuncles differ from folliculitis, which is more superficial as pus remains within the epidermis.

Erysipelas is an acute, superficial, non-necrotizing, dermal/deep dermal infection that is caused mainly by beta-hemolytic streptococci of group A, but also group B, C, and G, and rarely by staphylococci.¹⁶ The clinical diagnosis is based on findings of sharply demarcated, shiny erythematous plaques that appear suddenly and are tender to the touch, with associated local swelling and fever.

Cellulitis is a skin infection that extends deeper into the subcutaneous tissues than erysipelas. These cellulitis infections may have associated regional lymphadenopathy and red streaking, and are more prone to local complications (abscess formation, necrosis) than is seen with erysipelas. With more of the skin loft (depth) involved, petechiae, ecchymoses, and bullae develop in the inflamed skin, which may result in a hemorrhagic appearance.¹⁷ Bulla formation is a frequent local complication of the disease and may be indicative of greater severity of infection.

If untreated, these superficial SSTIs can lead to regional and systemic complications. Consider the presentation of the toxic adolescent patient describing what he perceives to be superficial severe skin pain overlying a limb but not involving a nearby joint. He explains that he plays hockey and a month ago sustained an injury to his knee area from an opponent's skate that cut through his knee pad. The wound hardly bled and healed by secondary intention without additional medical attention. On exam, the skin surface appears undamaged and completely normal, yet the slightest touch causes significant pain. This exam is consistent with pain out of proportion to the exam, and other etiologies should be considered, such as thrombophlebitis, osteomyelitis, or deep space infection. There are well-described cases of septic

thrombophlebitis with acute osteomyelitis¹⁹ and endocarditis that can complicate the aftermath of SSTIs.¹⁸

Other bacterial associations with skin infection include *Pasteurella multocida* following cat or dog bites, *Vibrio* species after salt water exposure, *Aeromonas hydrophila* following immersion in fresh water, *Haemophilus influenzae* in periorbital cellulitis in children, or, rarely, epiglottitis in adults.

As another example, natural disasters such as the massive tsunami that struck southern Thailand on December 26, 2004, provide perhaps the greatest experience in managing acute SSTIs following aquatic injuries. Soon after the wave decimated the coastline, Hiransuthikul et al reported acute SSTIs in 515 of 777 (66.3%) patients with crush injuries to the legs transferred to four regional referral hospitals in Bangkok.¹⁹ Wounds and/or pus were cultured from 396 (76.9%) of these patients. The majority of specimens were polymicrobial (71.8%), and the most common organisms isolated were Gram-negative bacteria, including *Aeromonas* species (22.6%), *Escherichia coli* (18.1%), *Klebsiella pneumoniae* (14.5%), *Pseudomonas aeruginosa* (12.0%), and *Proteus* species (7.3%). Only 4.5% of the isolates were Gram-positive bacteria, most commonly staphylococcal species.¹⁹

Another group of investigators reported on a subset of European tsunami survivors who developed late-onset (median 60 days) chronic post-traumatic SSTI caused by rapidly growing marine mycobacteria.²⁰ These infections occurred in undamaged skin located near sutured traumatic wounds or skin grafts. These patients required antimycobacterial therapy, and healing was protracted, occurring within a year in most cases.

The forgoing cases demonstrate that a history of injury should be elicited from the patient, and the possibility of interval healing must be considered. Physicians need to think about the possibility of a retained foreign

Table 2. ALT-70 Prediction Tool for Lower Extremity Cellulitis

Factor	Score
Asymmetry: unilateral leg involvement	3
Leukocytosis: white blood cell count $\geq 10,000$	2
Tachycardia: heart rate ≥ 90 beats per minute	2
Age ≥ 70 years	2
With an ALT-70 score of 0 to 2, the positive likelihood ratio (LR+) is 1.21 and the negative likelihood ratio (LR-) is 0.09.	
With an ALT-70 score of 5 to 7, the LR+ is 2.10 and the LR- is 0.55.	

Table 3. LRINEC Prediction Tool for Necrotizing Fasciitis

Factor	Value	Score
Serum sodium	≥ 135 mEq/L	0
	< 135 mEq/L	2
Serum glucose	> 180 mg/dL	1
	≤ 180 mg/dL	0
Serum creatinine	> 1.6 mg/dL	2
	≤ 1.6 mg/dL	0
C-reactive protein	< 150	0
	≥ 150	4
Leukocyte count	$< 15,000$	0
	15,000 to 25,000	1
	$> 25,000$	2
Hemoglobin	> 13.5 g/dL	0
	11.0 to 13.5 g/dL	1
	< 11.0 g/dL	2


body, slow-growing organisms, and the potential for deeper tissue contamination dating back to an index event even a year out. In addition, the emerging problem of CA-MRSA, which is responsible for fully half of the cases of cellulitis with purulent exudates, also causes infections in patients lacking typical risk factors (hospitalization, long-term care factors).²¹

Necrotizing fasciitis represents a severe soft tissue infection with

associated high morbidity and mortality.²² Risk factors include diabetes mellitus, injection drug use, hypertension, and obesity. Necrotizing fasciitis may present with significant pain, erythema, ecchymosis, purulence, and/or crepitus caused by subcutaneous air. Systemic signs of sepsis may be present. The most commonly infected sites include the perineum, lower limbs, upper limbs, and axillary region.²³


Prompt recognition of necrotizing fasciitis is essential to ensure timely

Figure 2. Ultrasonographic Appearance of Subcutaneous Abscess



Note sonographic appearance of fluid-filled sac (dark appearance).

Figure 3. Bedside Ultrasound Appearance of Cellulitis Demonstrating “Cobblestoning” Appearance of Subcutaneous Edema



administration of broad-spectrum antibiotics and surgical debridement.²⁴ Several studies have identified

predictors of mortality, which may include advanced age, female gender, signs of sepsis or septic shock, obesity,

diabetes, chronic heart disease, cirrhosis, skin necrosis, tachycardia, serum creatinine, hypertension, multifocal infection, severe peripheral vascular disease, hospital-acquired infection, and polymicrobial or Gram-negative infections.^{25,26,27,28}

Diagnostic Tests

SSTIs are diagnosed primarily by clinical findings. Cellulitis typically is a clinical diagnosis, supported by the clinical findings of erythema, warmth, edema, and pain. An abscess is supported by the findings of localized erythema, swelling, and fluctuance. Unilateral findings are most suggestive of cellulitis as compared to venous stasis, which often is bilateral.

Individual laboratory tests have limited value in establishing the diagnosis of cellulitis. Multifactorial prediction tools incorporating laboratory tests may be more useful. Such prediction tools have been developed for lower extremity cellulitis and necrotizing fasciitis.

Researchers recently developed a diagnostic prediction tool for lower extremity cellulitis from 259 patients admitted from the ED for presumed cellulitis.²⁹ (See Table 2.) Ultimately, 180 (69.5%) of the patients were diagnosed with cellulitis, while 79 (30.5%) were diagnosed with other disorders, termed pseudocellulitis. The derived decision tool, named ALT-70, had a score range from 0 to 7. The higher the score, the more likely the patient had cellulitis. The authors divided the patients into three categories based on the score, along with a recommended course of action. Patients with a score of 0 to 2 had a negative predictive value of 83%, so the recommended course of action was reassess. Patients with scores of 3 and 4 had indeterminate predictive values, so the recommended course of action was to consult a specialist, such as a dermatologist, who could perform skin biopsy and other tests. Patients with scores of 5 to 7 had a positive predictive value > 82%, so the recommended course of action was to treat for cellulitis with antibiotics.

Table 4. Empiric Treatment of Skin and Soft Tissue Infections

Conditions	Suggested Antibiotic	Duration of Therapy
Purulent cellulitis	Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, minocycline, or linezolid	5-10 days
Nonpurulent cellulitis	Clindamycin or linezolid, or combination therapy with doxycycline or minocycline, plus a beta-lactam, such as amoxicillin-clavulanate	5-10 days
Complicated cellulitis in hospitalized patients	Intravenous vancomycin, oral or intravenous linezolid, intravenous daptomycin, intravenous telavancin, or intravenous or oral clindamycin	7-10 days
Impetigo	Topical mupirocin or retapamulin, or oral therapy to include dicloxacillin or cephalexin	5 days
Ecthyma	Dicloxacillin or cephalexin	7 days
Necrotizing fasciitis	Vancomycin or linezolid plus piperacillin-tazobactam or a carbapenem Alternatives may include ceftolozane-tazobactam, ceftazidime-avibactam in association with an anti-anaerobic agent (metronidazole or clindamycin)	

Elevated C-reactive protein (CRP) levels may be seen in necrotizing fasciitis.³⁰ The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) is a score that may be used to identify patients at higher risk for necrotizing fasciitis. The LRINEC is comprised of serum sodium, glucose, creatinine, CRP, leukocyte count, and hemoglobin.³¹ LRINEC scores range from 0 to 13, with higher scores associated with increased risk of necrotizing fasciitis. The authors who developed the score proposed threshold values of 6 for moderate (50% to 75%) risk of necrotizing fasciitis and a score 8 for high (> 75%) risk of necrotizing fasciitis. (See Table 3.)

A systematic review of 16 studies with a total of 846 patients found the mean LRINEC score was 6.06 for patients with necrotizing fasciitis and 2.45 for patients without.³¹ The receiver operating characteristic (ROC) curve was calculated using LRINEC scores; the fitted ROC area was 0.927, indicating the LRINEC was an excellent test to discriminate

patients with necrotizing fasciitis from those without.

The LRINEC has been criticized as lacking adequate sensitivity for excluding patients with low scores. Both prospective and retrospective studies have found that about 20% to 30% of patients with necrotizing fasciitis will have LRINEC scores of 5 or less.^{31,32}

Blood cultures have a low rate of positivity, a low rate of impact on clinical decision making, and a high false-positive rate, and are not recommended routinely for the treatment of cellulitis, even in febrile patients.^{33,34,35,36,37} Similarly, cultures of the soft tissues are low yield and of limited usefulness in clinical decision making.^{38,39}

Several recent studies have demonstrated the utility of bedside ultrasound in clinical decision making, with findings that may result in a change in management.^{40,41} Ultrasound is of value in differentiating cellulitis from abscess.^{42,43} (See Figures 2 and 3.) Ultrasound also may

be of particular use in the evaluation of hand infections⁴⁴ and may help to identify foreign bodies. Sonographic evidence of necrotizing fasciitis may include subcutaneous air, abscess, edematous soft tissues, and/or muscle necrosis.⁴⁵

CT or magnetic resonance imaging (MRI) may be indicated for anatomic areas of concern for vascular or other anatomic involvement, such as the face, neck, pelvis, or perineum, or if necrotizing fasciitis or other deep space infection is suspected.^{46,47,48} Plain radiographs are of limited utility unless there is a history of trauma.⁴⁹ Plain radiographs may be used to screen for radiopaque foreign bodies, osteomyelitis, or soft tissue gas suggestive of suspected deep space necrotizing infections. However, radiographs lack sufficient sensitivity to be the sole test for any of these conditions.

Differential Diagnosis

Several conditions may mimic cellulitis. Venous stasis may present with edema and erythema, but most commonly is bilateral and may be associated with chronic skin changes, such as hyperpigmentation, lichenification, or ulcerations. Deep venous thrombosis may present with unilateral pain, swelling, and erythema, and may be differentiated from cellulitis by ultrasonography of the lower extremities. An abscess may be distinguished from cellulitis by ultrasonographic appearance.

Empiric Treatment

Empiric treatment is indicated for cellulitis, as the precise pathogen rarely is known. Tetanus immunization should be updated if not current.

Guidelines from the Infectious Diseases Society of America may be used to guide empiric therapy. (See Table 4.) Purulent cellulitis should be treated with 5-10 days of antibiotics, such as clindamycin, trimethoprim-sulfamethoxazole, doxycycline, minocycline, or linezolid, to cover MRSA. Nonpurulent cellulitis should be treated with 5-10 days of antibiotics,

Table 5. Antibiotic Doses for Outpatient Treatment

Drug	Adult Dose	Pediatric Dose	Comments
Penicillin VK	250-500 mg QID PO	25-75 mg/kg per day in 4 divided doses PO	For nonpurulent cellulitis
Amoxicillin-clavulanate	875/125 mg BID PO	25 mg/kg per day of the amoxicillin component in 2 divided doses PO	For nonpurulent cellulitis and impetigo
Cephalexin	250-500 mg QID PO	25-50 mg/kg per day in 4 divided doses PO	Use in penicillin-allergic patients except those with immediate hypersensitivity reactions
Dicloxacillin	250-500 mg QID PO	25-50 mg/kg per day in 4 divided doses PO	Agent of choice in adults with methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA)
Clindamycin	300-450 mg QID PO	25-30 mg/kg per day in 3 divided doses PO	Important option for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) treatment children
Doxycycline	200 mg once PO, followed by 100 mg BID PO	Not recommended for age < 8 years	Limited recent clinical experience
Minocycline	200 mg once PO, followed by 100 mg BID PO	Not recommended for age < 8 years	Limited recent clinical experience
Trimethoprim-sulfamethoxazole	1-2 double strength tablets BID PO Each tablet: 800 mg trimethoprim and 160 mg sulfamethoxazole	8-12 mg/kg per day based on trimethoprim component in 2 divided doses PO	For purulent cellulitis
Linezolid	600 mg BID PO	< 5 years old: 30 mg/kg per day in 3 divided doses PO 5-11 years old: 20 mg/kg per day in 2 divided doses PO ≥ 12 years old: 600 mg BID PO	Use for MRSA and complicated purulent skin infection Retail price for 600 mg # 28 tablets about \$3,000-4,000, but significant discounts available
Mupirocin 2% ointment	Apply to lesions BID	Apply to lesions BID	Retail price for 22 gram tube about \$52
Retapamulin 1% ointment	Apply to lesions BID	Apply to lesions BID	Retail price for 15 gram tube about \$250

such as clindamycin, or linezolid, or combination therapy with doxycycline or minocycline, plus a beta-lactam/beta-lactamase inhibitor combination such as amoxicillin/clavulanate, to cover beta-hemolytic streptococci.⁵⁰ Oral therapy is as efficacious as intravenous therapy for uncomplicated cellulitis.⁵¹ (See Table 5.)

Risk factors for failure of outpatient therapy include fever, chronic leg ulcers, chronic edema or lymphedema, prior cellulitis in the same area, and

cellulitis of a wound site.⁵²

Complicated cellulitis in hospitalized patients should be treated with broad-spectrum antibiotics, including empiric therapy for MRSA. Antibiotic choices may include intravenous vancomycin, oral or intravenous linezolid, intravenous daptomycin, intravenous telavancin, or intravenous or oral clindamycin. Therapy should be given for 7 to 14 days.⁵³

Recurrent infections should be managed with appropriate antibiotic

therapy, as well as environmental management, including frequent hand washing, covering wounds, and environmental hygiene of household surfaces. For patients with recurrent infections despite appropriate therapy and environmental hygiene, decolonization may be considered with a regimen including nasal mupirocin and a topical antiseptic solution, such as chlorhexidine or dilute household bleach.

Impetigo should be treated with

topical mupirocin or retapamulin, or with oral therapy to include dicloxacillin or cephalexin. Similarly, ecthyma may be treated with oral therapy, such as dicloxacillin or cephalexin.⁵³

If necrotizing fasciitis is suspected, prompt administration of broad-spectrum antibiotics and surgical consultation for emergent debridement are indicated.⁵⁴ Antibiotic regimens may include vancomycin or linezolid plus piperacillin-tazobactam or a carbapenem.⁵³ Alternatives may include ceftolozane-tazobactam, ceftazidime-avibactam in association with an anti-anaerobic agent (metronidazole or clindamycin). Other newer treatment alternatives may include ceftaroline, ceftobiprole, oritavancin, or dalbavancin.⁵⁵

Disposition

Disposition of patients with cellulitis should be determined based on severity of disease, presence of systemic symptoms, ability to ambulate, ability to care for self, and ability to comply with outpatient medical therapy and follow-up. Uncomplicated cellulitis may be treated with outpatient oral antibiotic therapy. Complicated or severe infections require inpatient parenteral therapy. Outpatient parenteral therapy may be considered for select cases.^{56,57} For patients who may require a single dose of intravenous therapy, this may be given in the ED or an ambulatory setting, followed by outpatient antibiotics.⁵⁸

References

1. Raff AB, Kroshinsky D. Cellulitis: A review. *JAMA* 2016;316:325-337.
2. Christensen KL, Holman RC, Steiner CA, et al. Infectious disease hospitalizations in the United States. *Clin Infect Dis* 2009;49:1025-1035.
3. Mills AM, Chen EH. Are blood cultures necessary in adults with cellulitis? *Ann Emerg Med* 2005;45:549.
4. Tracey EH, Modi B, Micheletti RG. Pemetrexed-induced pseudocellulitis reaction with eosinophilic infiltrate on skin biopsy. *AM J Dermatopathol* 2017;39:e1-e2.
5. Moran GJ, Talan DA. Cellulitis: Commonly misdiagnosed or just misunderstood? *JAMA* 2017;317:760-761.
6. Weng QY, Raff AB, Cohen JM, et al. Cost and consequences associated with misdiagnosed lower extremity cellulitis. *JAMA Dermatol* 2016 Nov 2. [Epub ahead of print.]
7. Levell NJ, Wingfield CG, Garioch JJ. Severe lower limb cellulitis is best diagnosed by dermatologists and managed with shared care between primary and secondary care. *Br J Dermatol* 2011;164:1326-1328.
8. Talan DA, Salhi BA, Moran GJ, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. *West J Emerg Med* 2015;16:89-97.
9. Elliot AJ, Cross KW, Smith GE, et al. The association between impetigo, insect bites and air temperature: A retrospective 5-year study (1999-2003) using morbidity data collected from a sentinel general practice network database. *Fam Pract* 2006;23:490-496.
10. Bernard P. Management of common bacterial infections of the skin. *Curr Opin Infect Dis* 2008;21:122-128.
11. McNamara DR, Tleyieh IM, Barbari EF, et al. Incidence of lower-extremity cellulitis: A population-based study in Olmsted county, Minnesota. *Mayo Clin Proc* 2007;82:817-821.
12. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): Case-control study. *BMJ* 1999;318:1591-1594.
13. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: A series with community follow-up. *Br J Dermatol* 2006;155:947-950.
14. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible *Staphylococcus aureus* in a German village by stringent decolonization, 2002-2005. *Clin Infect Dis* 2007;44:e88-e95.
15. Hota B, Ellenbogen C, Hayden BK, et al. Community-associated methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections at a public hospital: Do public housing and incarceration amplify transmission? *Arch Intern Med* 2007;167:1026-1033.
16. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N Engl J Med* 2006;355:666-674.
17. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the management of skin and soft tissue infections. *Clin Infect Dis* 2005;41:1373-1406.
18. LePage AA, Hess EP, Schears RM. Septic thrombophlebitis with acute osteomyelitis in adolescent children: A report of two cases and review of the literature. *Int J Emerg Med* 2008;1:155-159.
19. Hiransuthikul N, Tantisirawat W, Lertutsahakul K, et al. Skin and soft-tissue infections among tsunami survivors in southern Thailand. *Clin Infect Dis* 2005;41:e93-e96.
20. Appelgren P, Farnebo F, Dotevall L, et al. Late-onset posttraumatic skin and soft-tissue infections caused by rapidly growing mycobacteria in tsunami survivors. *Clin Infect Dis* 2008;47:e11-e16.
21. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant *Staphylococcus aureus*: An emerging threat. *Lancet Infect Dis* 2005;5:275-286.
22. Faraklas I, Yang D, Eggerstedt M, et al. A multi-center review of care patterns and outcomes in necrotizing soft tissue infections. *Surg Infect (Larchmt)* 2016;17:773-778.
23. Misiakos EP, Bagias G, Papadopoulos I, et al. Early diagnosis and surgical treatment for necrotizing fasciitis: A multi-center study. *Front Surg* 2017;4:5.
24. Hadeed GJ, Smith J, O'Keefe T, et al. Early surgical intervention and its impact on patients presenting with necrotizing soft tissue infections: A single academic center experience. *J Emerg Trauma Shock* 2016;9:22-27.
25. Moore A, Levy BH, Prematilake C, Dissanaika S. The prediction predicament: Rethinking necrotizing soft tissue infections mortality. *Surg Infect* 2015;16:813-821.
26. Jabbour G, El-Menyar A, Peralta R, et al. Pattern and predictors of mortality in necrotizing fasciitis patients in a single tertiary hospital. *World J Emerg Surg* 2016;11:40.

27. Hua C, Sbidian E, Hemery F, et al. Prognostic factors in necrotizing soft-tissue infections (NSTI): A cohort study. *J Am Acad Dermatol* 2015;73:1006-12.e8.
28. Khamnuan P, Chongruksut W, Jearwattananok K, et al. Necrotizing fasciitis: Risk factors of mortality. *Risk Manag Healthc Policy* 2015;8:1-7.
29. Raff AB, Weng QY, Cohen JM, et al. A predictive model for diagnosis of lower extremity cellulitis: A cross-sectional study. *J Am Acad Dermatol* 2017;76:618-625.e2.
30. Borschitz T, Schlicht S, Siegel E, et al. Improvement of a clinical score for necrotizing fasciitis: 'Pain out of proportion' and high CRP levels aid the diagnosis. *PLoS One* 2015;10:e0132775.
31. Bechar J, Sepehripour S, Hardwicke J, Filobos G. Laboratory risk indicator for necrotizing fasciitis (LRINEC) score for the assessment of early necrotizing fasciitis: A systematic review of the literature. *Ann R Coll Surg Engl* 2017;99:341-346.
32. Burner E, Henderson SO, Burke G, et al. Inadequate sensitivity of laboratory risk indicator to rule out necrotizing fasciitis in the emergency department. *West J Emerg Med* 2016;17:333-336.
33. Long B, Koyfman A. Best clinical practice: Blood culture utility in the emergency department. *J Emerg Med* 2016;51:529-539.
34. Paolo WF, Poreda AR, Grant W, et al. Blood culture results do not affect treatment in complicated cellulitis. *J Emerg Med* 2013;45:163-167.
35. van Daalen FV, Kallen MC, van den Bosch CMA, et al. Clinical condition and comorbidity as determinants for blood culture positivity in patients with skin and soft-tissue infections. *Eur J Clin Microbiol Infect Dis* 2017; Jun 7. [Epub ahead of print].
36. Bauer S, Aubert CE, Richli M, Chuard C. Blood cultures in the evaluation of uncomplicated cellulitis. *Eur J Intern Med* 2016;36:50-56.
37. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. *J Infect* 2012;64:148-155.
38. Pallin DJ, Bry L, Dwyer RC, et al. Toward an objective diagnostic test for bacterial cellulitis. *PLoS One* 2016;11:e0162947.
39. Piso RJ, Pop R, Wieland M, et al. Low sensitivity of needle aspiration cultures in patients with cellulitis/erysipelas. *Springerplus* 2016;5:1578.
40. Iverson K, Haritos D, Thomas R, Kannikeswaran N. The effect of bedside ultrasound on diagnosis and management of soft tissue infections in a pediatric ED. *Am J Emerg Med* 2012;30:1347-1351.
41. Alsaawi A, Alrajhi K, Alshehri A, et al. Ultrasonography for the diagnosis of patients with clinically suspected skin and soft tissue infections: A systematic review of the literature. *Eur J Emerg Med* 2015; Oct 19. [Epub ahead of print].
42. Subramaniam S, Bober J, Chao J, Zehtabchi S. Point-of-care ultrasound for diagnosis of abscess in skin and soft tissue infections. *Acad Emerg Med* 2016;23:1298-1306.
43. Barbic D, Chenkin J, Cho DD, et al. In patients presenting to the emergency department with skin and soft tissue infections what is the diagnostic accuracy of point-of-care ultrasonography for the diagnosis of abscess compared to the current standard of care? A systematic review and meta-analysis. *BMJ Open* 2017;7:e013688.
44. Marvel BA, Budhram GR. Bedside ultrasound in the diagnosis of complex hand infections: A case series. *J Emerg Med* 2015;48:63-68.
45. Shyy W, Knight RS, Goldstein R, et al. Sonographic findings in necrotizing fasciitis in necrotizing fasciitis: Two ends of the spectrum. *J Ultrasound Med* 2016;35:2273-2277.
46. Maroldi R, Farina D, Ravanelli M, et al. Emergency imaging assessment of deep neck space infections. *Semin Ultrasound CT MR* 2012;33:432-442.
47. Hayeri MR, Ziai P, Shehata ML, et al. Soft-tissue infections and their imaging mimics: From cellulitis to necrotizing fasciitis. *Radiographics* 2016;36:1888-1910.
48. Carbonetti F, Cremona A, Carusi V, et al. The role of contrast enhanced computed tomography in the diagnosis of necrotizing fasciitis and comparison with the laboratory risk indicator for necrotizing fasciitis (LRINEC). *Radiol Med* 2016;121:106-121.
49. Stranix JT, Lee ZH, Bellamy J, et al. Indications for plain radiographs in uncomplicated lower extremity cellulitis. *Acad Radiol* 2015;22:1439-1442.
50. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011;52:e18-e55.
51. Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: A randomized non-inferiority trial. *J Antimicrob Chemother* 2015;70:581-586.
52. Peterson D, McLeod S, Woolfrey K, McRae A. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. *Acad Emerg Med* 2014;21:526-531.
53. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59:e10-e52.
54. Leiblein M, Marzi I, Sander AL, et al. Necrotizing fasciitis: Treatment concepts and clinical results. *Eur J Trauma Emerg Surg* 2017; May 8. [Epub ahead of print].
55. Menichetti F, Giuliano S, Fortunato S. Are there any reasons to change our behavior in necrotizing fasciitis with the advent of new antibiotics? *Curr Opin Infect Dis* 2017;30:172-179.
56. Rentala M, Andrews S, Tiberio A, et al. Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis. *Am J Emerg Med* 2016;34:1273-1275.
57. Hodgson KA, Huynh J, Ibrahim LF, et al. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy. *Arch Dis Child* 2016;101:886-893.
58. Claeys KC, Lagnf AM, Patel TB, et al. Acute bacterial skin and skin structure infections treated with intravenous antibiotics in the emergency department or observational unit: Experience at the Detroit Medical Center. *Infect Dis Ther* 2015;4:173-186.

CME Questions

- A 26-year-old zookeeper presents with concern for a progressive skin infection he says began after cleaning cat cages yesterday. The patient has a low-grade fever. His left lower leg is erythematous, tender, and warm. There is serosanguinous drainage and fat is exposed at the base of 2.0 x 0.5 cm deep wound. What skin disorder does this presentation describe?

 - Cellulitis
 - Erysipelas
 - Furunculosis
 - Impetigo
 - Psoriasis
- In addition to antibiotics, what other measures should be taken to treat non-necrotizing cellulitis?

 - Incision and debridement where indicated
 - Abscess localization and drainage assisted by ultrasound
 - Wound elevation and immobilization
 - Tetanus booster if last booster was more than five years ago
 - All of the above
- Pseudocellulitic states can mimic cellulitis, making diagnosis challenging. What feature often helps to distinguish the two?

 - History of chemotherapy and widespread rash
 - Bilateral vs. unilateral limb involvement
 - Dependent edema vs. lymphedema
 - Evidence of venous insufficiency and stasis
 - History of insect bites and finding of focal erythema

DocuSign Envelope ID: B84A8704-A263-478A-947C-74C6427D17C1

UNITED STATES POSTAL SERVICE® (All Periodicals Publications Except Requester Publications)

Statement of Ownership, Management, and Circulation

1. Publication Title Primary Care Reports	2. Publication Number 1 0 4 0 _ 2 4 9 7	3. Filing Date 10/1/17
4. Issue Frequency Monthly	5. Number of Issues Published Annually 12	6. Annual Subscription Price \$379.00
7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4®) 950 East Paces Ferry Road NE, Ste. 2850, Atlanta Fulton County, GA 30326-1180		Contact Person Journey Roberts Telephone (Include area code) (919) 377-9913
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer) 111 Corning Rd, Ste 250, Cary, NC 27518-9238		
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank) Publisher (Name and complete mailing address) Relias Learning LLC, 111 Corning Rd, Ste 250, Cary, NC 27518-9238 Editor (Name and complete mailing address) Leslie Coplin, same as publisher Managing Editor (Name and complete mailing address) Shelly Mark, same as publisher		
10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)		
Full Name	Complete Mailing Address	
Relias Learning LLC	111 Corning Rd, Ste 250, Cary, NC 27518-9238	
Bertelsmann Learning LLC	1745 Broadway, New York, NY 10019	
11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box <input checked="" type="checkbox"/> None		
Full Name	Complete Mailing Address	
12. Tax Status (For completion by nonprofit organizations authorized to mail at nonprofit rates) (Check one) The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: <input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months <input type="checkbox"/> Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)		

PS Form 3526, July 2014 (Page 1 of 4 (see instructions page 4)) PSN: 7530-01-000-9931 **PRIVACY NOTICE:** See our privacy policy on www.usps.com.

- Methicillin-resistant *Staphylococcus aureus* is a serious condition in a healthcare setting because:

 - it is resistant to first- and second-line antibiotics.
 - it is acquired in hospitals and community settings.
 - it occurs in otherwise healthy young people who may be carriers.
 - carriers may exhibit variable contagious patterns.
 - All of the above
- All of the following are acceptable empiric agents for single-agent outpatient treatment of uncomplicated cellulitis *except*:

 - amoxicillin.
 - clindamycin.
 - linezolid.
 - trimethoprim-sulfamethoxazole.
- Which type of soft tissue infection has the highest morbidity and mortality?

 - Necrotizing fasciitis
 - Purulent cellulitis
 - Purulent myositis
 - Subcutaneous abscess

13. Publication Title Primary Care Reports		14. Issue Date for Circulation Data Below September 2017	
15. Extent and Nature of Circulation		Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Total Number of Copies (Net press run)		183	173
b. Paid Circulation (By Mail and Outside the Mail)	(1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541 (Include paid distribution above nominal rate, advertiser's proof copies, and exchange copies)	131	137
	(2) Mailed In-County Paid Subscriptions Stated on PS Form 3541 (Include paid distribution above nominal rate, advertiser's proof copies, and exchange copies)	0	0
	(3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®	9	10
	(4) Paid Distribution by Other Classes of Mail Through the USPS (e.g., First-Class Mail®)	11	1
c. Total Paid Distribution [Sum of 15b (1), (2), (3), and (4)]		151	148
d. Free or Nominal Rate Distribution (By Mail and Outside the Mail)	(1) Free or Nominal Rate Outside-County Copies included on PS Form 3541	8	10
	(2) Free or Nominal Rate In-County Copies Included on PS Form 3541	0	0
	(3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g., First-Class Mail)	0	0
	(4) Free or Nominal Rate Distribution Outside the Mail (Carriers or other means)	5	5
e. Total Free or Nominal Rate Distribution (Sum of 15d (1), (2), (3) and (4))		13	15
f. Total Distribution (Sum of 15c and 15e)		164	163
g. Copies not Distributed (See Instructions to Publishers #4 (page #3))		19	10
h. Total (Sum of 15f and g)		183	173
i. Percent Paid (15c divided by 15f times 100)		92%	91%

* If you are claiming electronic copies, go to line 16 on page 3. If you are not claiming electronic copies, skip to line 17 on page 3.

UNITED STATES POSTAL SERVICE® (All Periodicals Publications Except Requester Publications)

16. Electronic Copy Circulation		Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Paid Electronic Copies			
b. Total Paid Print Copies (Line 15c) + Paid Electronic Copies (Line 16a)			
c. Total Print Distribution (Line 15f) + Paid Electronic Copies (Line 16a)			
d. Percent Paid (Both Print & Electronic Copies) (16b divided by 16c × 100)			

I certify that 50% of all my distributed copies (electronic and print) are paid above a nominal price.

17. Publication of Statement of Ownership

If the publication is a general publication, publication of this statement is required. Will be printed in the November 2017 issue of this publication. Publication not required.

18. Signature and Title of Editor, Publisher, Business Manager, or Owner



Chief operating officer

Date

20-Sep-2017

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties).

PRIMARY CARE REPORTS

CME Objectives

Upon completion of this educational activity, participants should be able to:

- Summarize recent, significant studies related to the practice of primary care medicine;
- Evaluate the credibility of published data and recommendations related to primary care medicine;
- Discuss the advantages and disadvantages of new diagnostic and therapeutic procedures in the primary care setting.

Is there an article or issue you'd like posted to your website? Interested in a custom reprint?

There are numerous opportunities to leverage editorial recognition to benefit your brand.

Call us at (800) 688-2421 or email Reprints@AHCMedia.com to learn more.

Discounts are available for group subscriptions, multiple copies, site-licenses, or electronic distribution. For pricing information, please contact our Group Account Managers at:

Phone: (866) 213-0844
Email: Groups@AHCMedia.com

To reproduce any part of AHC newsletters for educational purposes, please contact The Copyright Clearance Center for permission:

Email: info@copyright.com
Website: www.copyright.com
Phone: (978) 750-8400

PRIMARY CARE REPORTS SUPPLEMENTS ARE AVAILABLE ONLINE

The November 2017 issues of *Pharmacology Watch* and *Clinical Briefs in Primary Care* are now available. We welcome your feedback and appreciate your continued support as a subscriber to *Primary Care Reports*.

Access Your Issues Online!

Visit AHCMedia.com and go to My Account to log in.

EDITOR IN CHIEF

Gregory R. Wise, MD, FACP
Associate Professor of Medicine
Oscar Boonshoft School of Medicine
Wright State University
Sole Shareholder
Kettering Physicians Network
Dayton, OH

EDITORIAL BOARD

Nancy J.V. Bohannon, MD, FACP
Private Practice
San Francisco, CA

Clara L. Carls, DO
Program Director
Hinsdale Family Medicine Residency
Hinsdale, IL

Norton J. Greenberger, MD
Clinical Professor of Medicine
Harvard Medical School
Senior Physician
Brigham & Women's Hospital
Boston, MA

Udaya Kabadi, MD
Professor
University of Iowa
School of Medicine
Iowa City, IA

Norman Kaplan, MD
Professor of Internal Medicine
Department of Internal Medicine
University of Texas Southwestern
Medical School
Dallas, TX

Dan L. Longo, MD, FACP
Professor of Medicine
Harvard Medical School
Deputy Editor,
The New England Journal of Medicine
Boston, MA

David B. Nash, MD, MBA
Dean
Jefferson School of Population Health
Thomas Jefferson University
Philadelphia, PA

Karen J. Nichols, DO, FACOI
Dean
Professor, Internal Medicine
Midwestern University
Chicago College of Osteopathic
Medicine
Downers Grove, IL

Allen R. Nissenon, MD
Professor of Medicine
Director of Dialysis Program
University of California Los Angeles
School of Medicine

Kenneth L. Noller, MD
Professor and Chairman
Department of OB/GYN
Tufts University School of Medicine
Boston, MA

Robert W. Piepho, PhD, FCP
Professor Emeritus of Pharmacology
and Toxicology
Deputy Editor
Dean Emeritus
University of Missouri Kansas City
School of Pharmacy
Kansas City, MO

Robert E. Rakel, MD
Department of Family and
Community Medicine
Baylor College of Medicine
Houston, TX

Glen D. Solomon, MD, FACP
Professor and Chair
Department of Internal Medicine
Wright State University
Boonshoft School of Medicine
Dayton, OH

Leon Speroff, MD
Professor of Obstetrics and
Gynecology
Oregon Health Sciences University
School of Medicine
Portland, OR

Robert B. Taylor, MD
Professor and Chairman
Department of Family Medicine
Oregon Health Sciences University
School of Medicine
Portland, OR

Roger D. Woodruff, MD
Associate Professor and Chair
Department of Family Medicine
Loma Linda University
Loma Linda, CA

© 2017 by AHC Media, a Relias Learning company. All rights reserved.

PRIMARY CARE REPORTS™ (ISSN 1040-2497) is published monthly by AHC Media, a Relias Learning company, 111 Corning Road, Suite 250, Cary, NC 27518. Telephone: (800) 688-2421.

Executive Editor: Leslie Coplin
Executive Editor: Shelly Mark
AHC Media Editorial Group Manager:
Terrey L. Hatcher
Senior Accreditations Officer:
Lee Landenberger

GST Registration No.: R128870672

Periodicals Postage Paid at Atlanta, GA 30304 and at additional mailing offices.

POSTMASTER: Send address changes to AHC Media, LLC, P.O. Box 74008694, Chicago, IL 60674-8694.

Copyright © 2017 by AHC Media, a Relias Learning company. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Back issues: \$26. Missing issues will be fulfilled by customer service free of charge when contacted within one month of the missing issue's date.

SUBSCRIBER INFORMATION

CUSTOMER SERVICE: (800) 688-2421

Customer Service Email Address:
Customer.Service@AHCMedia.com

Editorial Email Address:
lcoplin@reliaslearning.com

Website:
AHCMedia.com

SUBSCRIPTION PRICES

1 year with free AMA
Category 1/Prescribed credits: \$379
Add \$19.99 for shipping & handling

MULTIPLE COPIES:

Discounts are available for group subscriptions, multiple copies, site-licenses, or electronic distribution. For pricing information, please contact our Group Account Managers at Groups@AHCMedia.com or (866) 213-0844.

All prices U.S. only. U.S. possessions and Canada, add \$30 plus applicable GST. Other international orders, add \$30.

ACCREDITATION

Relias Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Relias Learning designates this enduring material for a maximum of 3 *AMA PRA Category 1 Credits™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This Enduring Material activity, *Primary Care Reports*, has been reviewed and is acceptable for up to 27 Prescribed credit(s) by the American Academy of Family Physicians. Term of approval begins 01/01/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each issue is approved for 2.25 Prescribed credits. Credit may be claimed for one year from the date of each issue. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Osteopathic Association has approved this continuing education activity for up to 2.5 AOA Category 2-B credits.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC Medical Knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This is an educational publication designed to present scientific information and opinion to health professionals, to stimulate thought, and further investigation. It does not provide advice regarding medical diagnosis or treatment for any individual case. It is not intended for use by the layman. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. Clinical, legal, tax, and other comments are offered for general guidance only; professional counsel should be sought for specific situations.

This CME activity is intended for primary care and family practice physicians. It is in effect for 36 months from the date of the publication.